Neurology News

The AMA has released 10 recommendations that physicians can share with patients to help keep them healthy in the new year.

People with MS who are being treated with rituximab are strongly encouraged to receive mRNA SARS-CoV-2 vaccines and booster doses more than 6 months after their last rituximab infusion, researchers reported in JAMA Network Open.

Singing may be a potential tool to promote communicative and psychosocial outcomes among patients with post-stroke aphasia, researchers reported in Brain Communications.

Healio’s Inside Private Equity blog series features legal insights on physician practice consolidation from Allison W. Shuren, JD, MSN, and J. Matthew Owens.

People experiencing persistent post-concussion symptoms were at a higher risk for depressive symptoms, researchers reported in JAMA Network Open.

Biomind Labs has completed the development of a novel sublingual formulation to be used in a phase 2 trial for a psychedelic-based candidate for the treatment of depression and anxiety in patients with Alzheimer’s disease.

An association between common antiepileptic drugs and incident Parkinson’s disease was found, researchers reported in JAMA Neurology.

The FDA has issued a complete response letter to Ipsen for its new drug application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation in people with fibrodysplasia ossificans progressiva.

KGK Sciences Inc. received a no objection letter from Health Canada to proceed with a phase 2a clinical trial evaluating the use of psilocybin for fragile X syndrome, the leading genetic cause of autism spectrum disorder.

Traumatic brain injury, PTSD and the apolipoprotein E4 gene showed strong associations with Alzheimer’s disease and related dementias, researchers reported in Alzheimer’s & Dementia.